| Patient | Lorraine Hansberry |
|---|---|
| Date of birth | 1930-05-19 |
| Identifiers | MRN HR-ML034-SYN-TD; SSN (made up) 000-34-7158 |
| Document date | 1963-08-10 |
| Author | Odette Marchetti-Fields, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Review after six cycles: restaging results and the decision for surgery. [S]
Ms. Hansberry returns two weeks after her sixth and last cycle before surgery. The diarrhea after cycle 5 settled within two days with loperamide, fluids and potassium, and with irinotecan reduced for cycle 6 she had only two loose stools. The restaging CT four days ago shows the tumor smaller and less contact with the vein, with no spread, and the tumor board recommends surgery; she met the surgeon and has chosen to go ahead. The interim CT ordered before cycle 5 was never scheduled. The cold-induced tingling is fading and her fingertips feel almost normal. Pain is 1 out of 10 and she takes oxycodone once every few days. She walks 30 minutes a day to prepare for surgery. Home fasting glucose is 115 to 135 mg/dL. She has had no bleeding on apixaban. She has written most mornings this month. She has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Treatment | Six cycles of modified FOLFIRINOX; irinotecan reduced for cycle 6 after grade 2 diarrhea |
| Restaging CT | Mass 2.1 cm from 3.1 cm; vein contact about 150 degrees; no arterial contact; no metastases |
| Decision | Pancreaticoduodenectomy with vein resection in two weeks |
| Effects | Diarrhea resolved; neuropathy fading |
| Preparation | Walking 30 minutes daily; protein supplements |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy improving; weight 54.2 kg; no fever |
| Gastrointestinal | Negative | Diarrhea resolved; stools formed; no nausea; no black stools |
| Neurological | Positive | Fingertip tingling fading; no weakness |
| Hematologic and lymphatic | Negative | No bleeding or bruising on apixaban |
| Respiratory | Negative | No cough or breathlessness |
| Psychiatric | Positive | Hopeful and nervous about surgery; PHQ-9 6; no thoughts of self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Pantoprazole 40 mg delayed-release oral tablet, one tablet by mouth once daily before breakfast | One tablet daily before breakfast | Oral route | 1963-04-20 | active | S |
| Ferric carboxymaltose 50 mg/mL injection, 750 mg intravenously, two doses one week apart | 750 mg intravenously; two doses one week apart | Intravenous route | 1963-04-24 to 1963-05-01 | completed | S |
| Oxycodone 5 mg oral tablet, one tablet by mouth every 4 hours as needed for pain | One tablet every 4 hours as needed | Oral route | 1963-05-04 | active | S |
| Senna 8.6 mg oral tablet, two tablets by mouth at night while taking oxycodone | Two tablets at night | Oral route | 1963-05-04 | active | S |
| Pancrelipase delayed-release capsule (lipase 36,000 units), two capsules with each meal and one with each snack | Two capsules with each meal, one with each snack | Oral route | 1963-05-04 to 1963-10-05 | completed | S |
| Oxaliplatin 5 mg/mL injection, 135 mg (85 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cycles | Day 1 every 14 days for six cycles | Intravenous route | 1963-05-18 to 1963-07-27 | completed | S |
| Irinotecan 20 mg/mL injection, 238 mg (150 mg/m2) intravenously over 90 minutes on day 1 of each 14-day cycle, cycles 1 to 5 | Day 1 every 14 days, cycles 1 to 5 | Intravenous route | 1963-05-18 to 1963-07-13 | completed | S |
| Irinotecan 20 mg/mL injection, 190 mg (120 mg/m2, one dose level lower) intravenously on day 1 of cycle 6 | Day 1 of cycle 6 | Intravenous route | 1963-07-27 to 1963-07-27 | completed | S |
| Leucovorin 10 mg/mL injection, 634 mg (400 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cycles | Day 1 every 14 days for six cycles | Intravenous route | 1963-05-18 to 1963-07-27 | completed | S |
| Fluorouracil 50 mg/mL injection, 3800 mg (2400 mg/m2) by continuous infusion over 46 hours through the port from day 1 of each 14-day cycle, for six cycles, with no bolus | 46-hour infusion from day 1 every 14 days for six cycles | Intravenous route | 1963-05-18 to 1963-07-29 | completed | S |
| Pegfilgrastim 6 mg/0.6 mL prefilled syringe, 6 mg under the skin on day 3 of each cycle, after the pump is disconnected | 6 mg on day 3 of each cycle | Subcutaneous route | 1963-05-20 to 1963-07-29 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea | One tablet every 8 hours as needed | Oral route | 1963-05-18 | active | S |
| Olanzapine 5 mg oral tablet, one tablet by mouth at night on days 1 to 4 of each cycle | One tablet at night on days 1 to 4 | Oral route | 1963-05-18 | active | S |
| Loperamide 2 mg oral capsule, two capsules at the first loose stool, then one after each loose stool, no more than eight a day unless directed | 4 mg at onset, then 2 mg after each loose stool | Oral route | 1963-05-18 | active | S |
| Apixaban 2.5 mg oral tablet, one tablet by mouth twice daily during chemotherapy, stopped three days before surgery | One tablet twice daily | Oral route | 1963-06-29 to 1963-08-21 | completed | S |
| Potassium chloride 20 mEq extended-release tablet, two tablets by mouth today, then one tablet daily for three days | 40 mEq today, then 20 mEq daily for three days | Oral route | 1963-07-16 to 1963-07-19 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1963-08-10 | Body height | 163 | cm | S |
| 1963-08-10 | Body weight | 54.2 | kg | S |
| 1963-08-10 | Body mass index (BMI) [Ratio] | 20.4 | kg/m2 | S |
| 1963-08-10 | Systolic blood pressure | 112 | mm[Hg] | S |
| 1963-08-10 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1963-08-10 | Heart rate | 80 | /min | S |
| 1963-08-10 | Respiratory rate | 16 | /min | S |
| 1963-08-10 | Body temperature | 36.6 | Cel | S |
| 1963-08-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1963-08-10 | Hemoglobin [Mass/volume] in Blood | 10.9 | g/dL | 12-15.5 g/dL | Low | S |
| 1963-08-10 | Leukocytes [#/volume] in Blood by Automated count | 7.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1963-08-10 | Neutrophils [#/volume] in Blood by Automated count | 4.9 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 1963-08-10 | Platelets [#/volume] in Blood by Automated count | 176 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1963-08-10 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 1963-08-10 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1963-08-10 | Creatinine [Mass/volume] in Serum or Plasma | 0.76 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1963-08-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1958)/1.73 sq M | 107 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1963-08-10 | Glucose [Mass/volume] in Serum or Plasma | 124 | mg/dL | 70-99 mg/dL | High | S |
| 1963-08-10 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-35 U/L | Normal | S |
| 1963-08-10 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 8-35 U/L | Normal | S |
| 1963-08-10 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 98 | U/L | 35-104 U/L | Normal | S |
| 1963-08-10 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1963-08-10 | Albumin [Mass/volume] in Serum or Plasma | 3.6 | g/dL | 3.5-5 g/dL | Normal | S |
| 1963-08-10 | Hemoglobin A1c/Hemoglobin.total in Blood | 7 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetes | High | S |
| 1963-08-10 | Cancer Ag 19-9 [Units/volume] in Serum or Plasma | 41 | U/mL | <=35 U/mL | High | S |
| 1963-08-10 | INR in Platelet poor plasma by Coagulation assay | 1 | {INR} | 0.8-1.2 | Normal | S |
| 1963-08-10 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 1963-08-10 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 1 | {score} | S |
Vital signs recorded on 1963-08-10; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 54.2 kg; blood pressure 112/72, pulse 80 |
| Eyes | No icterus |
| Abdomen | Soft, non-tender; no mass; port site clean |
| Neurological | Light touch at the fingertips almost normal; vibration and reflexes normal |
| Extremities | No leg swelling |
| Psychiatric | Calm, focused, asks about recovery time for writing |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Epigastric pain for about two months, boring through to the back and worse after meals and lying flat, with nausea, early fullness, a loss of 5 kg (8 percent of her weight), and pale, loose stools: an upper abdominal cause such as a bleeding ulcer or a pancreatic or duodenal tumor must be found. Upper endoscopy and pancreas-protocol CT booked this week | resolved | confirmed | R10.13 | S — Synthetic presenting problem anchored to the documented collapse in pain and the account of a suspected duodenal ulcer. Superseded by the diagnosis at the second visit. |
| Iron deficiency anemia from chronic upper gastrointestinal blood loss: black stools on and off for three weeks, two near-fainting spells, hemoglobin 9.1 g/dL, MCV 74 fL, ferritin 6 ng/mL | active | confirmed | D50.0 | S — Synthetic finding anchored to the documented account that she was told she had anemia and bleeding ulcers. |
| New hyperglycemia: A1c 6.6% and random glucose 132 mg/dL in a lean woman of 32 who is losing weight; new diabetes with weight loss can be the first sign of a pancreatic cancer, so it is to be confirmed and explained, not labeled type 2 | resolved | confirmed | R73.09 | S — Synthetic finding; superseded when diabetes due to the pancreatic cancer was recorded at the second visit. |
| Adenocarcinoma of the head of the pancreas, 3.1 cm, invading the duodenum, borderline resectable (tumor contact of more than half the circumference of the superior mesenteric vein, no arterial contact), no distant spread, CA 19-9 486 U/mL after biliary drainage; on EUS-guided biopsy; synthetic modern detail linked to her documented cancer, whose primary site the sources record differently | active | confirmed | C25.0 | S — Synthetic histology, site, stage and course; the sources say she died of cancer and differ on whether it was pancreatic, duodenal, or colonic with spread to the pancreas (R). See sources.md. |
| Diabetes due to the pancreatic cancer (pancreatogenic, type 3c): A1c 6.6% at intake and fasting glucose 141 mg/dL | active | confirmed | E08.9 | S — Synthetic consequence of the synthetic tumor. |
| Exocrine pancreatic insufficiency from obstruction of the pancreatic duct: pale, floating, loose stools after fatty meals and weight loss | active | confirmed | K86.81 | S — Synthetic consequence of the synthetic tumor; diagnosed clinically, as guidance allows in pancreatic cancer. |
| Cancer-related pain in the upper abdomen and back, 6 out of 10, with sleep broken by it | active | confirmed | G89.3 | S — Synthetic symptom of the synthetic tumor. |
| Obstruction of the distal common bile duct by the tumor, relieved by a covered metal stent placed at ERCP | active | confirmed | K83.1 | S — Synthetic consequence of the synthetic tumor. |
| Chemotherapy-induced diarrhea from irinotecan, grade 2 (five to six watery stools a day above her usual), starting on day 3 of cycle 5, with low potassium and magnesium and mild dehydration; no fever, blood or neutropenia; resolved | resolved | confirmed | K52.1 | S — Synthetic treatment effect; not a historical claim. |
| Oxaliplatin peripheral neuropathy, grade 1: tingling in the fingers and toes in the cold, lasting a few days after each cycle, with mild tingling at the fingertips between cycles; no effect on writing or buttons | active | confirmed | G62.0 | S — Synthetic common effect of oxaliplatin. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Restaging CT after chemotherapy before surgery | After completing therapy before surgery | Up to date | Four days ago: partial response; vein contact about 150 degrees; no arterial contact; no metastases |
| Imaging | Interim restaging CT | Every two months during chemotherapy before surgery | Deferred | A deviation: the interim CT ordered at cycle 4 was never scheduled. No harm resulted: CA 19-9 kept falling and today's CT shows a response without progression. Corrective action: the nurse navigator now tracks every imaging order to a booked date |
| Laboratory | CA 19-9 | At diagnosis after biliary drainage, every two cycles during treatment, before surgery, after surgery, then every three to six months | Completed today | 41 U/mL, from 210 at cycle 4 and 486 at diagnosis |
| Laboratory | Blood count with neutrophils and platelets | Before surgery | Completed today | Hemoglobin 10.9 g/dL, white cells 7.8, neutrophils 4.9, platelets 176 |
| Laboratory | Kidney and liver function, electrolytes and albumin before surgery | Within 30 days before surgery | Completed today | Sodium 138, potassium 4.1 mmol/L; creatinine 0.76 mg/dL, eGFR 107; ALT 24, AST 26, alkaline phosphatase 98 U/L, bilirubin 0.5 mg/dL; albumin 3.6 g/dL |
| Laboratory | INR before surgery | Before surgery | Completed today | 1.0 |
| Referral | Pancreatic tumor board and surgical oncology | After restaging | Up to date | Tumor board three days ago and surgical consultation: resection recommended and accepted |
| Medication safety | Anticoagulation around surgery | Before and after surgery | Completed today | Apixaban stopped three days before surgery; enoxaparin 40 mg daily for four weeks after it |
| Examination | Oxaliplatin neuropathy: symptoms and examination | At each visit after oxaliplatin | Completed today | Grade 1 and fading |
| Survey | Pain score and opioid review | Each visit | Completed today | Pain 1 out of 10; oxycodone once every few days |
| Self-management | Weight, nutrition and enzyme replacement | Each visit | Completed today | Weight 54.2 kg, 2 percent below the weight at diagnosis; protein supplements and walking to prepare for surgery |
| Laboratory | Glucose and home readings | Each visit and before each cycle | Completed today | Glucose 124 mg/dL |
| Laboratory | A1c | Every three months while treatment changes | Completed today | 7.0%, from 6.6% at the first visit |
| Examination | Dilated eye examination and urine albumin-to-creatinine ratio | At diagnosis of diabetes, then yearly | Deferred | Still outstanding (see the deviation at cycle 4); booked with the visit after surgery |
| Survey | Distress and depression screen (PHQ-9, GAD-7) | At diagnosis, at each treatment phase, and when symptoms change | Completed today | PHQ-9 6 |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (2026); Khorana AA, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34(21):2541-2556 (PMID 27247221) (2016); Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023); Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (PMID 32663120) (2020); American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2026 (classification of diabetes, including diabetes of the exocrine pancreas) (2026); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and anemia monographs (2026); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Surgery in two weeks. Primary care review about six weeks after surgery with the pathology. Call for fever, bleeding, or leg swelling before then. Next scheduled visit 1963-10-05: six weeks after pancreaticoduodenectomy: pathology, diabetes and enzyme replacement after surgery, and the plan for chemotherapy after surgery. [S]